Re: Amendment to Development and License Agreement dated March 21, 2023 Dear Sirs;Development and License Agreement • May 12th, 2023 • Biohaven Ltd. • Pharmaceutical preparations
We refer to the Development and License Agreement dated March 21, 2023 between Biohaven Therapeutics Ltd. (“Biohaven”) and Hangzhou Highlightll Pharmaceutical Co. Ltd. (“Highlightll”) relating to dual TYK2/JAK1 tyrosine kinase inhibitors (“License Agreement”). Capitalized terms shall have the meanings ascribed to them in the License Agreement unless otherwise defined herein.
AMENDMENT TO SHARE OPTION GRANT NOTICE AND OPTION AGREEMENTShare Option Grant Notice and Option Agreement • May 12th, 2023 • Biohaven Ltd. • Pharmaceutical preparations • Delaware
This Amendment to that certain Share Option Grant Notice and Option Agreement (this “Amendment”) is entered into by and between [Optionholder] (“Optionholder”) and Biohaven Ltd. (the “Company”), effective as of [●], 2023 (“Amendment Effective Date”). Capitalized terms used but not defined herein will have the meanings given to them in the Option Agreement.
DEVELOPMENT AND LICENSE AGREEMENT Dual TYK2/JAK1 InhibitorsDevelopment and License Agreement • May 12th, 2023 • Biohaven Ltd. • Pharmaceutical preparations • Delaware
This Development and License Agreement (the “Agreement”) is made and entered into effective as of March 21, 2023 (the “Effective Date”) by and between Hangzhou Highlightll Pharmaceutical Co. Ltd., having an office at RM 301/302, BLDG 4, Qiantang District, Hangzhou, China (“Highlightll”) and Biohaven Therapeutics Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands having an office at P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands (“Biohaven”). Highlightll and Biohaven are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
